Mesoblast (MESO) Stock Price, News & Analysis

Company Overview

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease. In addition, Mesoblast’s lead investigational candidate, remestemcel-L, is in late-stage development in the United States for the treatment of pediatric patients with steroid-refractory acute graft-versus-host disease. Beyond these programs, Mesoblast maintains a diversified pipeline targeting heart failure, low back pain due to disc degeneration, and other immune-driven disorders, with multiple Phase 2 and Phase 3 trials underway.

Headquartered in Melbourne, Australia, with a major corporate office in New York City, Mesoblast operates research and manufacturing facilities across North America, Europe, and the Asia–Pacific region. The company collaborates with strategic partners and regulatory authorities worldwide to advance its programs, ensuring broad geographic reach in both clinical development and commercial distribution.

Under the leadership of founder and CEO Dr. Silviu Itescu, Mesoblast emphasizes rigorous clinical research, regulatory compliance, and scalable manufacturing processes. The company’s management team combines expertise in cell biology, clinical development, and partnership licensing to support its mission of bringing transformative therapies to patients with high unmet medical needs.

Key Stats

• Today's Range: $14.76 to $15.22
• 50-Day Range: $13.69 to $16.61
• 52-Week Range: $9.88 to $21.50
• Volume: 153,711 shs
• Average Volume: 232,433 shs
• Market Capitalization: $1.92 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Mesoblast Stock Analysis - MarketRank™

Mesoblast scored higher than 22% of companies evaluated by MarketBeat, and ranked 796th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Mesoblast has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Mesoblast has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mesoblast are expected to grow in the coming year, from ($0.49) to ($0.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesoblast is -27.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesoblast is -27.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mesoblast has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.80% of the float of Mesoblast has been sold short.

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 17.91, which indicates bearish sentiment.

Change versus previous month

Short interest in Mesoblast has recently increased by 1.24%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mesoblast does not currently pay a dividend.

Dividend Growth

Mesoblast does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.93

News Sentiment

Mesoblast has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mesoblast this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $28,429,183.00 in company stock, which represents 1.4728% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Mesoblast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,429,183.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.43% of the stock of Mesoblast is held by institutions.

Company Calendar

• Last Earnings: 8/30/2023
• Today: 6/01/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MESO
• Previous Symbol: OTCMKTS:MBLTY
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: 61-3-9639-6030
• Employees: 80
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 1.58
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $17.20 million
• Price / Sales: 111.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.67 per share
• Price / Book: 3.18

Miscellaneous

• Outstanding Shares: 129,460,000
• Free Float: 105,122,000
• Market Cap: $1.92 billion
• Optionable: Optionable
• Beta: 2.05